Development of drug derivatives without cross-resistance to parent compounds.
Scheulen
M E
ME
Innere Universitätsklinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum, Essen, FRG.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D007939:Leukemia L1210 / Q000473:pathology; D008727:Methotrexate / Q000494:pharmacology; D011739:Pyrimethamine / Q000031:analogs & derivatives / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; C006308:metoprine; D004317:Doxorubicin; D004250:DNA Topoisomerases, Type II; D005978:Glutathione; D008727:Methotrexate; D011739:Pyrimethamine